Theravance Biopharma Inc Asset Resilience Ratio

Latest as of December 2025: 30.39%

Theravance Biopharma Inc asset resilience ratio. Theravance Biopharma Inc (TBPH) has an Asset Resilience Ratio of 30.39% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Theravance Biopharma Inc defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Liquid Assets

$147.55 Million

Cash + Short-term Investments

Total Assets

$485.57 Million

All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio of Theravance Biopharma Inc (2014–2025)

Asset resilience ratio of Theravance Biopharma Inc from 2014 to 2025. This chart shows how Theravance Biopharma Inc's Asset Resilience Ratio has changed over time. Read TBPH liabilities breakdown for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Theravance Biopharma Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Theravance Biopharma Inc.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	$0.00	0%
Short-term Investments	$147.55 Million	30.39%
Total Liquid Assets	$147.55 Million	30.39%

Asset Resilience Insights

Very High Liquidity: Theravance Biopharma Inc maintains exceptional liquid asset reserves at 30.39% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

Theravance Biopharma Inc Industry Peers by Asset Resilience Ratio

Compare Theravance Biopharma Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
HLB Co. Ltd KQ:028300	Biotechnology	3.29%
Tubize-Fin BR:TUB	Biotechnology	2.50%
Shanghai Medicilon Inc SHG:688202	Biotechnology	6.69%
Blue Jet Healthcare Limited NSE:BLUEJET	Biotechnology	13.81%
Hangzhou Biotest Biotech Co Ltd SHG:688767	Biotechnology	0.56%
Shouyao Holdings (Beijing) Co. Ltd. A SHG:688197	Biotechnology	79.76%
Shenzhen Weiguang Biological Products Co Ltd SHE:002880	Biotechnology	5.52%

Theravance Biopharma Inc Asset Resilience Ratio by Year (2014–2025)

Theravance Biopharma Inc asset resilience ratio by year from 2014 to 2025. The table below shows the annual Asset Resilience Ratio data for Theravance Biopharma Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	30.39%	$147.55 Million	$485.57 Million	+16.11pp
2024-12-31	14.27%	$50.55 Million	$354.16 Million	-2.19pp
2023-12-31	16.46%	$62.88 Million	$382.00 Million	+11.64pp
2022-12-31	4.83%	$29.31 Million	$607.40 Million	-17.45pp
2021-12-31	22.28%	$83.51 Million	$374.82 Million	-22.81pp
2020-12-31	45.08%	$211.47 Million	$469.06 Million	-9.40pp
2019-12-31	54.49%	$222.77 Million	$408.83 Million	+31.77pp
2018-12-31	22.71%	$127.25 Million	$560.24 Million	-36.10pp
2017-12-31	58.81%	$259.59 Million	$441.40 Million	+34.35pp
2016-12-31	24.46%	$156.39 Million	$639.25 Million	+4.56pp
2015-12-31	19.90%	$59.73 Million	$300.12 Million	-29.07pp
2014-12-31	48.97%	$165.40 Million	$337.77 Million	--

pp = percentage points

About Theravance Biopharma Inc

NASDAQ:TBPH USA Biotechnology

Market Cap

$876.92 Million

Market Cap Rank

#9203 Global

#2616 in USA

Share Price

$17.03

Change (1 day)

+0.00%

52-Week Range

$13.57 - $20.74

All Time High

$42.56